EP3565638B8 - Bicycle conjugate for treating cancer - Google Patents
Bicycle conjugate for treating cancer Download PDFInfo
- Publication number
- EP3565638B8 EP3565638B8 EP18700385.0A EP18700385A EP3565638B8 EP 3565638 B8 EP3565638 B8 EP 3565638B8 EP 18700385 A EP18700385 A EP 18700385A EP 3565638 B8 EP3565638 B8 EP 3565638B8
- Authority
- EP
- European Patent Office
- Prior art keywords
- treating cancer
- bicycle
- conjugate
- bicycle conjugate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443508P | 2017-01-06 | 2017-01-06 | |
| PCT/GB2018/050017 WO2018127699A1 (en) | 2017-01-06 | 2018-01-05 | Compounds for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3565638A1 EP3565638A1 (en) | 2019-11-13 |
| EP3565638B1 EP3565638B1 (en) | 2024-03-06 |
| EP3565638B8 true EP3565638B8 (en) | 2024-04-10 |
Family
ID=60957340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18700385.0A Active EP3565638B8 (en) | 2017-01-06 | 2018-01-05 | Bicycle conjugate for treating cancer |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US10624968B2 (en) |
| EP (1) | EP3565638B8 (en) |
| WO (1) | WO2018127699A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| US11730819B2 (en) * | 2016-12-23 | 2023-08-22 | Bicycletx Limited | Peptide derivatives having novel linkage structures |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| JP7152408B2 (en) | 2017-03-10 | 2022-10-12 | キアペグ ファーマシューティカルズ アクチエボラグ | releasable conjugate |
| WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP7301757B2 (en) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | Bicyclic peptide ligands with detectable moieties and uses thereof |
| WO2019034868A1 (en) * | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| JP2021515765A (en) | 2018-03-09 | 2021-06-24 | キアペグ ファーマシューティカルズ アクチエボラグ | Releaseable antibody conjugate |
| JP7438180B2 (en) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | Novel anti-LAG-3 antibody polypeptide |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| KR101987591B1 (en) * | 2018-08-06 | 2019-06-10 | 국립해양생물자원관 | Nucleic acids aptamer binding specifically to Ingenol mebutate |
| BR112021004689A2 (en) | 2018-09-12 | 2021-06-08 | Quiapeg Pharmaceuticals Ab | releasable glp-1 conjugates |
| US20210338681A1 (en) * | 2018-10-01 | 2021-11-04 | Secura Bio, Inc. | Combination therapies |
| JP2022512779A (en) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | Bicyclic peptide ligands and their use |
| GB201820288D0 (en) * | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| KR20210123295A (en) * | 2018-12-13 | 2021-10-13 | 바이사이클티엑스 리미티드 | Bicyclic peptide ligand specific for MT1-MMP |
| AU2020256098A1 (en) * | 2019-03-29 | 2021-10-28 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| JP2022528887A (en) * | 2019-04-02 | 2022-06-16 | バイスクルテクス・リミテッド | Bicycle toxin conjugates and their use |
| TW202108165A (en) | 2019-05-10 | 2021-03-01 | 英商拜西克爾德有限公司 | Methods for treating cancer |
| TW202110485A (en) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
| US20220298538A1 (en) * | 2019-09-05 | 2022-09-22 | Pamgene Bv | Kinase activity signatures for predicting the response of non-small-cell lung carcinoma patients to a pd-1 or pd-l1 immune checkpoint inhibitor |
| US11878009B2 (en) * | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| EP4045075A1 (en) * | 2019-10-16 | 2022-08-24 | Bicyclerd Limited | Methods for treating cancer |
| US20230391871A1 (en) * | 2020-10-22 | 2023-12-07 | The Regents Of The University Of California | Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams) |
| KR20230135586A (en) | 2021-01-24 | 2023-09-25 | 마이클 데이비드 포레스트 | ATP synthase inhibitors - cosmetic and therapeutic uses |
| CN114452403A (en) * | 2021-02-10 | 2022-05-10 | 同润生物医药(上海)有限公司 | Pharmaceutical composition containing bifunctional immune checkpoint/TGF beta inhibitor |
| AU2022328932A1 (en) * | 2021-08-17 | 2024-02-29 | Medshine Discovery Inc. | Polypeptide drug conjugate having novel structure and application thereof |
| GB202114282D0 (en) | 2021-10-06 | 2021-11-17 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02005675A (en) | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | PYRROLO[2,3 d]PYRIMIDINE COMPOUNDS. |
| PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
| KR100833371B1 (en) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (en) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Use of protein kinase n beta |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| CN1826331A (en) | 2003-04-03 | 2006-08-30 | 塞马福尔药业公司 | Pi-3 kinase inhibitor prodrugs |
| CA2527583C (en) | 2003-05-30 | 2013-12-17 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | Inhibition of syk kinase expression |
| RS55551B1 (en) | 2004-05-13 | 2017-05-31 | Icos Corp | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| ATE451381T1 (en) | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES THEREOF |
| SI1844337T1 (en) | 2005-01-24 | 2013-11-29 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| MX2007014049A (en) | 2005-05-12 | 2008-02-11 | Abbott Lab | Apoptosis promoters. |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| HUE028987T2 (en) | 2005-11-01 | 2017-01-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| ES2612196T3 (en) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| ATE471940T1 (en) | 2006-04-26 | 2010-07-15 | Hoffmann La Roche | THIENOÄ3,2-DÜPYRIMIDINE DERIVATIVE SUITABLE AS PI3K INHIBITOR |
| LT2530083T (en) | 2006-09-22 | 2016-09-26 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CN101861313B (en) | 2007-03-12 | 2014-06-04 | Ym生物科学澳大利亚私人有限公司 | Phenyl amino pyrimidine compounds and uses thereof |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
| PT2257624E (en) | 2008-02-05 | 2012-05-29 | Medical Res Council | Methods and compositions |
| KR20120108042A (en) | 2008-03-11 | 2012-10-04 | 인사이트 코포레이션 | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| EP2343081A1 (en) * | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| PL3214091T3 (en) | 2010-12-09 | 2019-03-29 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130072598A1 (en) * | 2011-03-18 | 2013-03-21 | Board Of Regents Of The University Of Nebraska | Thermoplastics from Distillers Dried Grains and Feathers |
| EP2764140B1 (en) * | 2011-10-07 | 2017-08-30 | Bicycle Therapeutics Limited | Modulation of structured polypeptide specificity |
| PL3215518T3 (en) | 2014-10-29 | 2021-08-23 | Bicyclerd Limited | Bicyclic peptide ligands specific for mt1-mmp |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| EP3544621A1 (en) | 2016-11-27 | 2019-10-02 | BicycleRD Limited | Methods for treating cancer |
| MX2019007367A (en) | 2016-12-23 | 2020-01-27 | Bicycletx Ltd | Peptide ligands for binding to mt1-mmp. |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| CA3116504A1 (en) | 2018-10-30 | 2020-05-07 | Bicyclerd Limited | Bt1718 for use in treating cancer |
| EP3935069A1 (en) | 2019-03-04 | 2022-01-12 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| TW202108165A (en) | 2019-05-10 | 2021-03-01 | 英商拜西克爾德有限公司 | Methods for treating cancer |
| EP4045075A1 (en) | 2019-10-16 | 2022-08-24 | Bicyclerd Limited | Methods for treating cancer |
-
2018
- 2018-01-05 US US15/862,964 patent/US10624968B2/en active Active
- 2018-01-05 EP EP18700385.0A patent/EP3565638B8/en active Active
- 2018-01-05 WO PCT/GB2018/050017 patent/WO2018127699A1/en unknown
-
2019
- 2019-12-16 US US16/714,938 patent/US11433137B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10624968B2 (en) | 2020-04-21 |
| EP3565638A1 (en) | 2019-11-13 |
| WO2018127699A1 (en) | 2018-07-12 |
| US11433137B2 (en) | 2022-09-06 |
| EP3565638B1 (en) | 2024-03-06 |
| US20200215199A1 (en) | 2020-07-09 |
| US20180200378A1 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3565638B8 (en) | Bicycle conjugate for treating cancer | |
| EP3641770A4 (en) | Methods for treating cancer | |
| EP3488001A4 (en) | Treating cancer | |
| EP3473270A4 (en) | Antibody-drug conjugate | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| HK1255412A1 (en) | Axl-specific antibody-drug conjugates for cancer treatment | |
| EP3288382A4 (en) | Methods for treating cancer | |
| EP3189082A4 (en) | Anti-pd-l1 conjugates for treating tumors | |
| AU2017260425A1 (en) | Combination therapy for cancer treatment | |
| EP3615083A4 (en) | Raf-degrading conjugate compounds | |
| EP3407978A4 (en) | Combination therapy for treating cancer | |
| EP3285773A4 (en) | Combination therapy for treating cancer | |
| EP3606962A4 (en) | Methods for treating cd73hi tumors | |
| EP3678663A4 (en) | Combination therapy for treating cancer | |
| EP3405203A4 (en) | Methods for treating cancer | |
| IL287644A (en) | Cytarabine conjugates for cancer therapy | |
| EP3389634A4 (en) | Methods for treating cancer | |
| EP3440112A4 (en) | Methods for treating cancer | |
| EP3474854A4 (en) | Cancer treatment combinations | |
| EP3258965A4 (en) | Combination therapy for cancer treatment | |
| EP3389652A4 (en) | Methods for treating cancer | |
| EP3892282A4 (en) | Combination for treating cancer | |
| EP3600341A4 (en) | Gemcitabine derivatives for cancer therapy | |
| EP3268046A4 (en) | Conjugates for treating diseases | |
| EP3407909A4 (en) | Cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190717 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200710 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40017381 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602018066151 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61P0035000000 Ipc: A61K0047650000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0035000000 Ipc: A61K0047650000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 7/56 20060101ALI20230317BHEP Ipc: A61K 38/08 20190101ALI20230317BHEP Ipc: A61K 47/64 20170101ALI20230317BHEP Ipc: A61P 35/00 20060101ALI20230317BHEP Ipc: A61K 47/65 20170101AFI20230317BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20230411 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230504 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| INTG | Intention to grant announced |
Effective date: 20230918 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| RAP4 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: BICYCLERD LIMITED |
|
| RIN2 | Information on inventor provided after grant (corrected) |
Inventor name: TEUFEL, DANIEL PAUL Inventor name: BENNETT, GAVIN |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018066151 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |